Pre-Conference Course

OSTEOPOROSIS: ESSENTIALS OF DENSITOMETRY, DIAGNOSIS AND MANAGEMENT COURSE
Wed, November 28 13.30 - 17.10
13.30	Welcome and Opening Remarks — N. Pocock and A. Mithal
13.40	Overview of Osteoporosis — N. Pocock
14.30	Bone Measurement Device Operating Principles — S. Baldwin
15.20	Coffee Break
15.40	X-Ray Science, Radiation Safety and Quality Assurance — N. Pocock
16.20	Clinical Evaluation of Bone Health — D. Chan
Thu, November 29 08.00 - 17.00
08.00	Use of Bone Densitometry for the Diagnosis of Osteoporosis — J. Center
08.50	Fracture Risk Assessment — S. Baldwin
09.40	Monitoring Treatment of Osteoporosis — J. Wark
10.30	Coffee Break
10.50	Clinical Management Part 1: Non-Pharmacologic, Estrogen & SERM Treatment — S. Ferrari
11.40	Clinical Management Part 2: Pharmacological Treatment Continued — J. Center
12.30	Lunch Break
13.30	Clinical Management Part 3: Further Pharmacologic Treatment Considerations — M. Chandran
14.20	Principles of DXA Scan Interpretation — N. Pocock
15.10	Coffee Break
15.30	Principles of Reporting DXA Scans — N. Pocock
16.20	Cases for Discussion — N. Pocock

Conference

Thu, November 29 Fri, November 30 Sat, December 1
17.30	OPENING CEREMONY Welcome — C. Cooper, J. A. Kanis & M. Chandran Best clinical papers of 2018 — R. Rizzoli Inclusion of diversity in science — S. Brennan Olsen Hearing the Consumer voice — G. Lyubomirsky Osteoporosis, global challenge, local impacts — L. March Conclusion
19.30 20.30	Welcome Cocktail

Thu, November 29 Fri, November 30 Sat, December 1
08.00 19.00	EXHIBITION AREA OPEN
08.15	PLENARY SESSION I Improving the identification of high risk patients Chair: J. A. Kanis & E. Seeman Can FRAX be improved — J. A. Kanis CTF/FLS: what have we achieved — C. Cooper New imaging modalities — S. Ferrari
09.30	ORAL COMMUNICATIONS SESSION I Chair: J. Eisman 9.30 — OC1 — T-SCORE AS AN INDICATOR OF FRACTURE RISK ON THERAPY: EVIDENCE FROM ROMOSOZUMAB VS ALENDRONATE TREATMENT IN THE ARCH TRIAL — C. Tolman 9.40 — OC2 — DENOSUMAB COMPARED WITH RISEDRONATE IN GLUCOCORTICOID-TREATED SUBJECTS: RESULTS FROM THE FINAL 24-MONTH ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY — C. Tolman 9.50 — OC3 — VITAMIN D SUPPLEMENTATION IN PREGNANCY: A RANDOMIZED DOUBLE-BLIND CONTROLLED TRIAL — R. Khadgawat
10.00	INDUSTRY-SPONSORED SATELLITE SYMPOSIUM (Detailed programme here)
11.00	PLENARY SESSION II Similarities and differences in fracture risk and treatments respone: Asia vs West (IOF-OA session) Chair: C. Cooper (IOF) & G. Lyubomirsky (OA) BMD and other parameters of bone in Asia vs West — K. Sanders FRAX: intervention threshold in Asia vs West — E. Lau Response to osteoporosis treatment: is it the same in Asian and Caucasian (benefit/risk including AFF) — P. Ebeling
12.30	INDUSTRY-SPONSORED LUNCH SYMPOSIUM (Detailed programme here)
13.30	BREAK AND POSTER VIEWING SESSION
14.00	MEET-THE-EXPERT SESSIONS Recent Fracture: when and how to treat osteoporosis — J.-K. Lee Chronic renal failure: how to assess and manage bone fragility? — P. Ebeling Vitamin D: which & how much? — A. Mithal Protein intake and supplement in fracture patient — R. Rizzoli
14.45	PLENARY SESSION III Quality of life in musculoskeletal diseases - ESCEO symposium Chair: R. Rizzoli & E. Biver Introduction — O. Bruyère Assessment of quality of life in osteoporosis — J.-M. Kaufman Assessment of quality of life in osteoarthritis — C. Cooper Assessment of quality of life in sarcopenia — F. Buckinx Discussion & Conclusion
16.15	INDUSTRY-SUPPORTED SESSION: IOF - APOA JOINT SESSION (more information here) Osteoporosis - Orthopedic Surgery in Asia Pacific, The Missing Link? Introduction — S. Ferrari Osteoporosis in Asia Pacific — P. Ebeling Orthopedic Surgery in Asia Pacific — D. Choon IOF-APOA Collaboration - “The Link” — J. K. Lee Launch of the IOF-APOA collaboration and Promising Future — C. Cooper
17.00	ORAL COMMUNICATIONS SESSION II Chair: M. Chandran 17.00 — OC4 — ANTI-OSTEOPOROSIS MEDICATIONS ARE ASSOCIATED WITH DECREASED MORTALITY AFTER HIP FRACTURE — Y. Li 17.10 — OC5 — ASIA-PACIFIC BONE ACADEMY FRACTURE LIAISON SERVICE EDUCATIONAL INITIATIVE — P. Ebeling 17.20 — OC6 — INCREASED CORTICAL POROSITY AND REDUCED TRABECULAR DENSITY ARE NOT NECESSARILY SYNONYMOUS WITH BONE LOSS AND MICROSTRUCTURAL DETERIORATION — E. Seeman
17.30 19.00	CNS ROUNDTABLE Mapping calcium intake Chair: B. Dawson-Hughes & A. Mithal Dietary calcium intake worldwide (Ca map) — B. Dawson-Hughes Consequences of low calcium intake in the Asia Pacific region — R. Rizzoli Calcium supplements and fracture prevention — A. Mithal Calcium intake and its implication in China — W. Xia Roundtable: Potential strategies to improve calcium intake - What is feasible within the low intake countries

Thu, November 29 Fri, November 30 Sat, December 1
08.00 17.00	EXHIBITION AREA OPEN
08.15	MEET-THE-EXPERT SESSIONS Falls prevention: is it possible — W.-L. Hsu Bone loss in early menopause: to treat or not? — A. Vincent Genetic markers of bone fragility: what have we learned — E. Duncan Can we trust bone turnover markers to improve fracture assessment — H. Morris
09.00	PLENARY SESSION IV Assessment and management of bone fragility beyond idiopathic osteoporosis (IOF-ANZBMS session) Chair: E. Biver & P. Croucher (ANZBMS) Fracture prevention in cancer patients — E. Biver Fracture prevention in diabetes patients — M. Chandran When to suspect a genetic disorder? — J. Eisman
10.15	ORAL COMMUNICATIONS SESSION III Chair: J. Center 10.15 — OC7 — EFFECTS OF TERIPARATIDE ON HIP AND UPPER LIMB FRACTURES IN PATIENTS WITH OSTEOPOROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS — M. Hassanzai 10.25 — OC8 — DIGITAL X-RADIOGRAMMETRY COMBINED WITH MAMMOGRAPHY TO SCREEN POSTMENOPAUSAL WOMEN FOR REDUCED BONE MINERAL DENSITY — A. Rao 10.35 — OC9 — DO DEFINITIONS OF SARCOPENIA PREDICT FRACTURE RISK INDEPENDENT OF FRAX, FALLS AND BMD? (A META-ANALYSIS OF THE OSTEOPOROTIC FRACTURES IN MEN (MROS) STUDY) — H. Johansson 10.45 — OC10 — ASSESSING CLINICAL UTILITY (IMPACT) OF GENETIC PROFILING IN FRACTURE RISK ASSESSMENT: A DECISION CURVE ANALYSIS APPROACH — T. Ho-Le
11.00	PLENARY SESSION V New insights in the management of knee osteoarthritis - ESCEO Symposium Chair: C. Cooper & F. Cicuttini Welcome — C. Cooper The 2014-2016 ESCEO algorithm for the management of knee osteoarthritis — O. Bruyère New insights on the safety of anti-osteoarthritis medications — E. Dennison New clinical evidence supporting the use of SYSADOAs as a first-line background treatment in knee osteoarthritis — J.-Y. Reginster, G. Honvo, A. Geerinck, O. Bruyère Update of the 2014-2016 ESCEO algorithm for the managment of knee osteoarthritis — C. Cooper Discussion & Conclusion — C. Cooper
12.30	INDUSTRY-SPONSORED SATELLITE SYMPOSIUM (Detailed programme here)
13.30	BREAK AND POSTER VIEWING SESSION
14.00	IOF-OA-ANZBMS JOINT SESSION Chair: G. Lyubomirsky & B. Dawson-Hughes Exercise and osteoporosis — B. Beck Monetary cost of osteoporosis — J. A. Kanis Morbidity and mortality of osteoporosis — J. Center
14.45	IOF-AGNOVOS HEALTHCARE YOUNG INVESTIGATOR AWARDS Chair: A. Mithal 14.51 — P118 — ORAL BISPHOSPHONATE USE AND ALL-CAUSE MORTALITY IN PATIENTS WITH ADVANCED (STAGE IIIB+) CHRONIC KIDNEY DISEASE: A POPULATION-BASED COHORT STUDY — D. Alarkawi 15.00 — P050 — PREDICTION OF FRACTURES IN MEN WITH DYSGLYCAEMIA USING FRAX (AUS) — K. Holloway-Kew 15.09 — P137 — ATYPICAL FEMUR FRACTURES IN AN AUSTRALIAN HOSPITAL SETTING: INCIDENCE, PATIENT RISK FACTORS AND DENSITOMETRIC CHARACTERISTICS — H. Nguyen 15.18 — P046 — ASSOCIATIONS BETWEEN PAIN AT MULTIPLE SITES AND PREVALENT AND INCIDENT FRACTURES IN OLDER ADULTS — F. Pan 15.27 — P011 — MID-CALF SKELETAL MUSCLE DENSITY AND ITS ASSOCIATIONS WITH ACCELEROMETER- DETERMINED PHYSICAL ACTIVITY, BONE HEALTH AND INCIDENT 12-MONTH FALLS IN OLDER ADULTS: THE HEALTHY AGEING INITIATIVE — D. Scott 15.36 — P083 — PERSISTENT HIGH-IMPACT ACTIVITY AND FITNESS DURING ADOLESCENCE AND EARLY ADULTHOOD AND BONE DENSITY AND MICROARCHITECTURE IN EARLY ADULTHOOD — Y. Yang
14.45	MEET-THE-EXPERT SESSIONS Osteosarcopenia — G. Duque Glucocorticoid osteoporosis — E. Dennison Assessment of physical strength and performance — F. Buckinx
15.45 17.00	PLENARY SESSION VI Osteoporosis treatment: update Chair: J. K. Lee & S. Ferrari Benefit/Risk of long term treatment — S. Ferrari Fracture risk off therapy — E. Dennison Closing the gap in the treatment of patients at imminent risk of fracture: role of the new anabolic agents — E. Biver